Cytokinetics (NASDAQ:CYTK) CEO Sells $471,600.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $62.88, for a total transaction of $471,600.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares of the company’s stock, valued at approximately $17,514,846.72. This trade represents a 2.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Down 1.9%

NASDAQ CYTK traded down $1.17 on Tuesday, hitting $61.62. The company’s stock had a trading volume of 1,935,741 shares, compared to its average volume of 2,140,254. Cytokinetics, Incorporated has a 1-year low of $54.30 and a 1-year high of $88.31. The company’s 50-day moving average is $71.47 and its 200 day moving average is $73.28. The firm has a market cap of $7.67 billion, a PE ratio of -8.53 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. Cytokinetics’s revenue was down 57.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.12) EPS. On average, equities analysts expect that Cytokinetics, Incorporated will post -5.98 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CYTK. JPMorgan Chase & Co. raised their target price on Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded Cytokinetics from a “sell” rating to a “hold” rating in a research report on Monday. Truist Financial increased their price target on Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics in a research note on Friday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $140.00 price objective on shares of Cytokinetics in a research report on Monday, August 31st. Eighteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $106.06.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Additional ACACIA-HCM analyses indicated that aficamten improved exercise performance across multiple measures in patients with non-obstructive HCM. The presentation also addressed treatment response, dose titration and safety, strengthening the case for aficamten’s potential clinical and commercial value. Cytokinetics Announces Additional Data from ACACIA-HCM
• Positive Sentiment: Reports highlighted exercise-capacity improvements and responder data for aficamten, suggesting that meaningful benefits may extend beyond a narrow subgroup of patients. This is positive for expectations surrounding future regulatory filings and market adoption. Cytokinetics Highlights Aficamten Responder Data
• Positive Sentiment: Coverage characterized the Phase 3 results as gains in non-obstructive HCM and suggested that aficamten’s multi-domain benefits could materially improve the investment thesis for Cytokinetics. Cytokinetics Phase 3 Aficamten Gains
• Neutral Sentiment: Analyst and media coverage remains mixed: some commentary points to substantial upside based on aficamten and Cytokinetics’ pipeline, while other reports say the stock is difficult to pin down following the strong heart-drug updates. Cytokinetics Stock Analysis
• Negative Sentiment: Despite the favorable data, aficamten’s ultimate regulatory outcome, launch timing and commercial uptake remain uncertain. Comparisons with other biotech companies and a recent upgrade to a “Hold” rating provide limited direct catalysts and may be contributing to cautious trading. Wall Street Zen Upgrades Cytokinetics to Hold

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently modified their holdings of the company. Mirador Capital Partners LP increased its position in shares of Cytokinetics by 3.2% during the third quarter. Mirador Capital Partners LP now owns 208,896 shares of the biopharmaceutical company’s stock worth $13,768,000 after buying an additional 6,526 shares during the period. GAMMA Investing LLC grew its holdings in Cytokinetics by 8.6% during the 3rd quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 213 shares during the period. Cim Investment Management Inc. raised its position in shares of Cytokinetics by 20.9% in the 2nd quarter. Cim Investment Management Inc. now owns 5,657 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 979 shares in the last quarter. Tidal Investments LLC raised its position in shares of Cytokinetics by 24.7% in the 2nd quarter. Tidal Investments LLC now owns 24,921 shares of the biopharmaceutical company’s stock worth $2,123,000 after acquiring an additional 4,938 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of Cytokinetics in the 2nd quarter valued at about $774,000.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.